Fact CheckerSign in

NCT06974773Recruiting

Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups

At-Home Transcranial Direct Current Stimulation (tDCS) Using the NettleEndo Device for Reducing Symptoms of Endometriosis - A Pivotal Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Source: ClinicalTrials.gov · Last updated 18 Dec 2025

Brief summary (registry, in English)

The goal of this clinical trial is to learn if a wearable brain stimulation device called NettleEndo can reduce chronic pelvic pain and improve wellbeing in women with endometriosis. The study also aims to assess the safety and usability of the device when used at home over several months. The main questions it aims to answer are: 1. Does at-home transcranial direct current stimulation (tDCS) reduce daily pain intensity in women with endometriosis? 2. Does the device also improve mood and sleep quality? Researchers will compare two groups-one receiving active brain stimulation and one receiving a sham (placebo) stimulation-to see if the active device provides greater improvements in symptoms. Participants will: 1. Use the NettleEndo device at home for 20 minutes per session, five times per week for 12 weeks 2. Be randomly assigned to receive either real or sham stimulation through the device 3. Complete daily and weekly symptom ratings through a mobile app 4. Be followed for 90 days after completing the intervention to monitor longer-term effects All activities are completed remotely using a smartphone app. Participants can contact the study team with questions at any time. The study is double-blind, meaning neither participants nor the researchers assessing outcomes will know who received active or sham treatment until the end of the trial.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
120 (estimated)
First submitted
6 May 2025
Start date
4 Dec 2025
Primary completion date
1 Jul 2026
Lead sponsor
Samphire Group, Inc.
NCT number
NCT06974773

What you commit to

  • Study type: Interventional
  • Planned participants: 120
  • From 4 Dec 2025 to the primary completion date, 1 Jul 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Metal implants/electronic devices in brain, head, or neck area
  • Treatment plan must be stabilized (≥6 weeks analgesic/ ≥6 months hormonal contraception, and crucially no new medication changes before randomization)
  • Participation in a neurotechnology or drug trial in the last 6 months.
  • Recent surgical intervention for endometriosis within 6 months of enrollment or planned surgical intervention for endometriosis during the study period.

Other illness

  • History of epileptic neurological conditions in the immediate family
  • Severe/untreated neurological disease (e.g., epilepsy or seizure disorders, stroke or transient ischemic attack \[TIA\], subarachnoid hemorrhage, traumatic brain injury \[TBI\] with persistent neurological deficits, brain tumors \[malignant or benign\], multiple sclerosis, Parkinson's disease, Alzheimer's disease or other dementias, Huntington's disease, cerebral aneurysms or arteriovenous malformations \[AVMs\], active central nervous system infections \[e.g., meningitis, encephalitis\], hydrocephalus, other neurodegenerative diseases not otherwise specified, or any other neurological condition that, in the opinion of the principal investigator, may increase risk or interfere with study participation or outcomes)
  • History of stroke, brain surgery, tumors, head trauma
  • Active skin lesions, open wounds, cuts, or infections on the scalp
  • Active scalp conditions (dermatitis, eczema, psoriasis)
  • Schizophrenia or bipolar disorder
  • History of suicidal behavior or clinically significant self-injurious behavior (e.g., one or more suicide attempts, non-suicidal self-injury \[NSSI\], or other behaviors indicative of intent to harm oneself), as determined by participant self-report.

Other

  • Pregnancy/breastfeeding or planning to become pregnant in next 6 months
  • Participating in any other clinical trial
  • Significant scarring/burns/other skin damage on scalp
  • Planning to commence any new treatment during intervention period
  • Lack of capacity to consent

Who the study is looking for

  • Female, 22-45 years old
  • Assigned female at birth
  • Fluent in English
  • Capacity to consent
  • Confirmed diagnosis of endometriosis by a qualified physician, via:
  • Laparoscopic surgery with biopsy-proven endometriosis, OR
  • Clear evidence of ovarian endometrioma or deep infiltrating endometriosis on ultrasound/MRI
  • Pain levels:
    • For menstruating participants, all of the following need to be met:
  • Regular menstrual cycles (21-35 days)
  • Mean DYS NRS ≥4 during menstrual bleeding days (over the last 28 days, self-assessed)
  • AND Mean NMPP NRS ≥4 during non-menstrual days (over the last 28 days, self-assessed)
    • For non-menstruating patients, all required:
  • Irregular/absent cycles OR post-hysterectomy OR surgically menopausal
  • Mean pelvic pain NRS ≥4 (over the last 28 days, self-assessed)
  • Pain present on ≥50% of days
  • Access to a smartphone with an internet data plan, phone must be iOS 13.4+, or Android 12+.
  • No hormonal contraception or at least 6 months of consistent adherence to any hormonal contraception (e.g., IUD, pill, injection).
  • Capacity to follow instructions and operate the study device.

Age in the registry: 22 years to 45 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Alethios, Inc.
Coordinator of this site? Confirm its status
San FranciscoUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.